SKNV, a leader in dermatologic innovation and custom prescription medications, proudly announces the launch of Kefunova Cream (Fluorouracil 5% / Calcipotriene 0.005%), a new prescription-only topical therapy developed in direct response to the needs of dermatology providers treating actinic keratosis (AK) and superficial basal cell carcinoma (sBCC).
“Kefunova is exactly what dermatology providers have been asking for—a trusted, high-quality option to target actinic keratosis and superficial basal cell carcinoma,” said Spencer Malkin, CEO of SKNV. “It answers a clear need in the clinical community for medications that integrate seamlessly into treatment plans. With a well-established mechanism and a formulation built for reliability and convenience, Kefunova is designed to support both dispensing in-office as well as prescribing direct-to-patient.”
Kefunova combines two time-tested active ingredients—Fluorouracil, a topical chemotherapy agent, and Calcipotriene, a vitamin D analog—to support a synergistic treatment approach. Together, they promote lesion clearance through enhanced immune activation and cell turnover.
Kefunova is manufactured at SKNV’s FDA-Registered 503B Outsourcing Facility, which operates under strict CGMP standards. The cream arrives ready-to-use and is available for both in-office dispensing and e-prescribing through EMR systems, giving providers the flexibility they need to meet growing demand. For patients nationwide facing the uncertainty of actinic keratosis or superficial basal cell carcinoma, Kefunova Cream represents hope—an affordable, accessible path toward healing and control.
